Once a neglected area of pharma research, companies are now investing heavily after several major commercial successes and with promising new avenues of research progressing.
In 1H financials, WuXi Biologics outlines positive developments across its ‘three major markets’, stressing that US growth is still strong despite US-China trade relations.
Dr Reddy’s Laboratories enters a $31m market with the launch of Versavo, a biosimilar of Roche’s Avastin in India, indicated for several types of cancer.
Increasing prevalence of chronic diseases and treatment with biologics is expected to boost the prefilled syringes market by 10% in the next few years.
The US District Court for the District of New Jersey ruled in Amgen’s favor on the validity of the two patents on Enbrel and the methods for making it.
The global market for regenerative medicines raised $4.8bn in the first half of 2019; a slowdown compared to the same period of 2018, though the sector is poised for additional growth, says ARM CEO.
EQT VIII Fund set to acquire majority interest in plasmid DNA supplier Aldevron, announces investments to support the expansion of its production capacity.
Alleged manipulated and potentially inaccurate clinical data in the BLA for the $2.1m Zolgensma spark possibility for criminal penalties against AveXis.
Compared to June 2018, the biomedical manufacturing output in Singapore city rises by 5% this month, concurrently boosting the country’s overall pharmaceuticals output growth.
